0001209191-22-034601.txt : 20220606 0001209191-22-034601.hdr.sgml : 20220606 20220606173051 ACCESSION NUMBER: 0001209191-22-034601 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220602 FILED AS OF DATE: 20220606 DATE AS OF CHANGE: 20220606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Powell Andrew Kenneth William CENTRAL INDEX KEY: 0001304113 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 22999057 MAIL ADDRESS: STREET 1: C/O COLLAGENEX PHARMACEUTICALS, INC. STREET 2: 41 UNIVERSITY DRIVE CITY: NEWTOWN STATE: PA ZIP: 18940 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-02 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001304113 Powell Andrew Kenneth William C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 0 0 0 Common Stock 2022-05-16 5 G 0 E 709 0.00 D 10500 D Common Stock 2022-06-03 4 M 0 3356 A 13856 D Stock Option (Right to Buy) 14.48 2022-06-02 4 A 0 15750 0.00 A 2032-06-01 Common Stock 15750 15750 D Restricted Stock Units 2022-06-02 4 A 0 4507 0.00 A Common Stock 4507 4507 D Restricted Stock Units 2022-06-03 4 M 0 3356 0.00 D Common Stock 3356 0 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. The shares underlying these restricted stock units vested on June 3, 2022. /s/ Mark Ballantyne, Attorney-in-Fact 2022-06-06